Printer Friendly

SYNERGEN ANNOUNCES NEW OFFICER AND MANAGEMENT APPOINTMENTS

 SYNERGEN ANNOUNCES NEW OFFICER AND MANAGEMENT APPOINTMENTS
 BOULDER, Colo., Aug. 19 /PRNewswire/ -- Synergen Inc. (NASDAQ: SYGN) announced today the promotion of James L. Redenbarger to vice president, operations and the appointment of two new hires, Sharon Tetlow to the position of treasurer and Barbara Dau Hoffman to the position of director of business development.
 "Synergen is strengthening its management across key functions, as we continue the transition from a research and development organization to a fully integrated biopharmaceutical company," explained Kenneth J. Collins, vice president of finance and administration.
 Redenbarger, who joined the company in 1982 as one of Synergen's first dozen employees, was promoted from director to vice president of operations. He most recently had overall project management responsibilities for the planning and construction of LakeCentre, Synergen's new manufacturing plant. Company functions under his direction include the library, purchasing, facilities, maintenance, construction, lab support, real estate, safety and materials management, including eventual distribution of finished products. Before joining Synergen, Redenbarger held management positions with a radiopharmaceutical company and a medical device manufacturer in Denver. He holds a B.S. in Microbiology from Purdue University.
 Tetlow joins the company from the finance group at Genentech Inc., where she most recently held the position of treasury manager and also held positions in financial planning and as marketing group controller. She was previously a financial analyst with Eli Lilly and Co. and did research at the Brookings Institution in Washington. Tetlow's responsibilities as treasurer at Synergen will include managing the company's investments, which are currently valued at $270 million; supervising the company's relationships with its commercial banks; risk management; and cash management including implementing a foreign exchange strategy. She holds an MBA from Stanford University and was graduated Magna Cum Laude from the University of Delaware.
 Hoffman was a portfolio manager at Denver-based INVESCO Trust Co., where she specialized in both publicly and privately held health sciences companies. Previously, she was a vice president and biotechnology and medical products securities analyst at Boettcher & Co. (now Kemper Securities) in Denver, which she joined in corporate finance. Hoffman also managed the financial analysis function at First Interstate Bank of Denver. At Synergen, Hoffman will be involved in identifying, assessing and negotiating product acquisition and collaboration agreements with biomedical research centers, universities and early-stage biopharmaceutical companies. She will also be involved in the implementation of Synergen's international product development strategy and will evaluate opportunities for potential company and/or technology acquisitions. Hoffman holds an MBA from the University of Chicago Graduate School of Business and a B.A. from Dartmouth College.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals. The company's research is targeted towards products to treat inflammatory diseases, chronic ulcers and neurological diseases. Synergen's lead product, ANTRIL(TM), is in clinical testing for seven indications including sepsis syndrome, rheumatoid arthritis and graft vs. host disease.
 -0- 8/19/92
 /CONTACT: Debra Bannister of Synergen, 303-938-6242/
 (SYGN) CO: Synergen Inc. ST: Colorado IN: MTC SU: PER


BB -- DV002 -- 1187 08/19/92 08:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 19, 1992
Words:508
Previous Article:C-COR ANNOUNCES 1992 YEAR-END FINANCIAL RESULTS, REVENUES UP 59 PERCENT
Next Article:CLOTHESTIME ANNOUNCES SECOND QUARTER RESULTS
Topics:


Related Articles
SYNERGEN REVISES PARTNERSHIP OFFER
SYNERGEN EXPANDS INTO EUROPE
SYNERGEN ADDS PATENT ATTORNEY AT BOULDER HEADQUARTERS
SYNERGEN APPOINTS DIRECTOR OF QUALITY
PHLX TO BEGIN TRADING LEAPS(TM) ON SYNERGEN
SYNERGEN DEDICATES NEW COMMERCIAL-SCALE MANUFACTURING PLANT
SYNERGEN BEGINS OPERATIONS IN JAPAN
NEW SYNERGEN SEPSIS TRIAL ENROLLS FIRST PATIENT; FOLLOW-UP TRIAL IN SEVERE SEPSIS PATIENTS BEGINS ON SCHEDULE
SYNERGEN FILES EUROPEAN MARKETING APPLICATION FOR ANTRIL IN SEVERE SEPSIS
SYNERGEN ELECTS NEW DIRECTOR TO BOARD

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters